MAAT INDEX

CLAIM #451 · Shake Shack Inc (SHAK) · 2023Q2 earnings call · Aug 3, 2023 · due Dec 31, 2024

next year, we're targeting a $2.3 million average roughly and we're going to hold to that.

Randy Garutti · CEO

PENDING
graded after results covering Dec 31, 2024 are reported

In context

n just kind of related that holding inflation constant. Do you think you could get that down even further in 2025 if given more time and with more focus on the issue? Randy Garutti: Yes. Thanks, Brian. I appreciate the question. I think broadly, the answer is yes on all fronts. Our commitment next year is both in drive-through costs and overall. But in our core formats, we're working towards new formats, more standardized, more templated, really optimizing the right size and doing so much to continue to bring that down over time. Teams doing great work on this. It takes time. Right. You've got shacks that are already designed and in place. Some of those will be more expensive drive-throughs. Some of those will be in more expensive places, like I named in New York, California. But overall, next year, we're targeting a $2.3 million average roughly and we're going to hold to that. as we look at years forward, depending on the mix of Shacks we believe and we are targeting lots of improvements in how we build our restaurants the way we do it, but still doing it in the Shake Shack way. So, we believe this is a great opportunity for us long-term, and we're committed to having this be an important fixture of our strategic plan in this coming year. Brian Mullan: Okay. thanks a lot. Just as a follow-up, I think a part of the recent cooperation agreement that the companies agree to work with some outside consultants to work at ways to be more efficient. My question is, just given all the various strategic efforts that are already underway internally and yielding progress. do you expect any consulting agreement would yield even more efficiencies above and beyond, and have y

Verify independently

SEC filings for SHAK · Claim quote is verbatim from the 2023Q2 earnings call.